Grunenthal Acquires Bayer Cancer Drug Stivarga
Analysis based on 9 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026
The deal is a modest, bolt-on asset sale for Bayer that trims a non-core oncology product while providing a small cash inflow, with limited effect on Bayer's overall valuation. For privately held Grunenthal, it is an accretive, low-risk expansion of its commercial portfolio, with the main market relevance being the modest transfer of an established oncology asset and its future revenue stream.
Grunenthal, a privately held German pharmaceutical company focused on pain management, announced an agreement with Bayer to acquire the cancer treatment Stivarga (regorafenib) for up to 375 million euros. Stivarga is an oral multikinase inhibitor approved in more than 90 markets for metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma. The transaction is subject to customary closing conditions, including approval by relevant regulatory authorities, and is expected to close by the end of 2026 or early 2027. Grunenthal estimates the medicine could contribute up to approximately 100 million euros to its consolidated EBITDA for the year ending 31 December 2027, assuming closing and full-year consolidation. Loss of exclusivity for Stivarga is anticipated in 2029 in the European Union and 2030 in the United States. The deal is the latest step in Grunenthal's M&A strategy of acquiring established medicines, following prior transactions including global rights to Nebido, rights to Cialis in Mexico, Brazil and Colombia, European Union — European rights to Crestor and Nexium, and other products. Grunenthal has invested around 2.6 billion euros in M&A transactions since 2017. CEO Gabriel Baertschi said the acquisition is immediately accretive and a strong strategic fit. Freshfields served as legal counsel to Grunenthal.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard